CBD and autism spectrum disorder: An update

by Duncan Fisher

November 15, 2022 - 2 min read

We have written before on the theoretical application of cannabidiol (CBD) to the problem of autism spectrum disorder (ASD). Preclinical data is not encouraging. Still, because CBD shows itself to be active in cognitive function in ever-more-surprising ways, much curiosity about its eventual utility in this disorder remains among researchers. 

Part of the problem in autism research is that the neurological definition of the syndrome itself remains elusive. In a way, administration of CBD, much of whose mechanism of action is known, could conceivably shed light on what ‘autism’ is, however. 

One of the things that CBD appears able to to is modulate excitatory glutamate and inhibitory γ-aminobutyric acid (GABA) levels in the brain, and that includes brain regions linked to ASD, like the basal ganglia and the dorsomedial prefrontal cortex. Because differences are known to exist in glutamate and GABA pathways in ASD, people’s response to CBD may differ, depending on whether or not they have ASD. 

To test this putative differential shift in glutamate and GABA levels, a team within King’s College London, the London and Maudsley NHS Foundation, and Johns Hopkins University have measured, against magnetic resonance spectroscopy, glutamate (Glx = glutamate + glutamine) and GABA+ (GABA + macromolecules) levels in 34 healthy men, 17 of them diagnosed with ASD, after a single oral dose of 600 mg CBD or placebo.* 

Across groups, CBD increased subcortical Glx, but decreased it in the cortex. CBD increased GABA+ across regions in controls, but decreased it significantly in the dorsomedial prefrontal cortex in the ASD cohort. CBD does modulate glutamate-GABA systems, and prefrontal-GABA systems do respond differently in ASD. 

The next steps would be to examine long-term administration of CBD, on brain and on behavior, and to evaluate whether acute brain changes predict durable response.

*Pretzsch CM, et al. Neuropsychopharmacology. 2019 Jul;44(8):1398-1405. doi: 10.1038/s41386-019-0333-8


DiolPure products contain PureForm CBD™ transformed from aromatic terpenes for pharmaceutical-grade purity. PureForm CBD™ is bioidentical to CBD extracted from hemp and cannabis, but free of any residual cannabinoids like THC or impurities or chemicals that can associate with traditional plant-derived production processes. 

The foregoing is a report on trends and developments in cannabinoid industry research. No product description herein is intended as a recommendation for diagnosis, treatment, cure or prevention of any disease or syndrome. 

Beyond glaucoma: Cannabinoids in ophthalmology

Beyond glaucoma: Cannabinoids in ophthalmology

Cannabinoids appear to have therapeutic potential in glaucoma. Beyond this, there may be further promise in ophthalmology.
Read More

December 05, 2022 1 min read

The endocannabinoid system and bone disease

The endocannabinoid system and bone disease

Stimulation of the endocannabinoid system modulates bone formation and bone resorption. There may be a role one day for targeted drugs in osteoporosis and some forms of bone cancer. 
Read More

December 02, 2022 1 min read

Sex differences, endocannabinoids, and pain

Sex differences, endocannabinoids, and pain

Sex differences in pain perception and analgesia is a burgeoning research field overall. What about cannabinoid analgesia specifically? 
Read More

December 01, 2022 2 min read

Follow us on Instagram

Net Orders Checkout

Item Price Qty Total
Subtotal $ 0.00

Shipping Address

Shipping Methods